Background. Chlamydia trachomatis is the most common notifiable disease in Canada, and extragenital sites are believed to serve as hidden reservoirs for ongoing transmission of infection. There are no specific Canadian screening guidelines for asymptomatic individuals from extragenital sites. We sought to determine the prevalence and factors associated with rectal C. trachomatis among female sexually transmitted infection (STI) clinic attendees in Alberta, Canada.
Chlamydia trachomatis infection is the most common notifiable disease in Canada; its incidence has increased steadily since 1998. In 2011, the national chlamydia rate was 290.2 per 100 000, whereas in Alberta the rate was 369.5 per 100 000 [1, 2] . The female-specific rate was 480.7 per 100 000, with females representing nearly two-thirds of all reported cases [2] . The majority of chlamydia cases are asymptomatic, but infection can result in significant morbidity including infertility, pelvic inflammatory disease, and chronic pelvic pain, and in untreated pregnant women can result in transmission from mother to child at the time of birth [3] . Extragenital sites are believed to serve as hidden reservoirs for ongoing transmission of infection, but there are no specific Canadian screening guidelines for individuals without extragenital symptoms [3] . American and British sexually transmitted disease guidelines recommend the use of nucleic acid amplification tests (NAATs) for rectal infections, but make no recommendations for rectal screening practices among females [4, 5] ; NAATs are now widely regarded as the preferred test for screening for both C. trachomatis and Neisseria gonorrhoeae due to their high sensitivity and specificity [6, 7] .
There are few published studies on the epidemiology of rectal C. trachomatis among women. Two studies evaluating NAAT rectal screening of females who reported anal intercourse (AI) reported a rectal C. trachomatis prevalence of 8.7% and 14.6%, and found increases in the detection of C. trachomatis cases of 9.5% and 23% [8, 9] . A San Francisco study of female sexually transmitted infection (STI) clinic attendees undergoing a pelvic examination and universally screened (regardless of symptoms or sexual activity) using NAAT reported a rectal C. trachomatis prevalence of 4.7% and a 14.8% increase in case-finding rates for C. trachomatis and N. gonorrhoeae, but no association between rectal chlamydia and AI [10] . The prevalence of rectal C. trachomatis was 4.8% among high-risk females universally screened from the rectal, genitourinary, and oropharyngeal sites at an STI clinic in the Netherlands [11] . The rectal site was positive in 68.5% of all chlamydia cases [11] . In another study, the sensitivity of using either symptom-based and/or sexual history-based screening was only 47% for female swingers compared to universal screening [12] . Further studies on universal screening of all anatomical sites have been recommended to further refine screening guidelines [8, 11] .
In July 2012, 2 STI clinics in Alberta, Canada, changed their testing algorithm for rectal C. trachomatis from cell culture to NAAT. We sought to determine the prevalence and characteristics of rectal chlamydia cases, as well as the impact of adding rectal screening to all women undergoing pelvic exams on chlamydia case finding.
METHODS

Anatomic Site-Specific Testing
All screening was performed at 2 STI clinics in Edmonton and Calgary, Alberta. Screening criteria differed at these 2 clinics. All women presenting to the Calgary STI Clinic were offered a pelvic examination and rectal screening. At the Edmonton clinic, an "express testing" stream was offered with urinebased testing only in low-risk women. Full clinical assessments including pelvic examinations were recommended for those who were symptomatic for any STI, were contacts to an STI, had reported AI since last testing, were sexually assaulted in the preceding 2 weeks, or were involved in sex work in the preceding 6 months.
NAAT specimens were collected for chlamydia at both STI clinics. Rectal specimens were collected by inserting a swab 2-3 cm into the rectum. Genitourinary specimens included either cervical or urine specimens. Cervical specimens were obtained by inserting a swab 1-2 cm into the endocervical canal, rotating the swab for 10-30 seconds. When a speculum examination was not clinically appropriate (eg, pregnant or vulvar lesions present), urine samples were obtained by collecting 20-30 mL of first-catch urine. Chlamydia trachomatis testing was conducted with Gen-Probe Aptima COMBO 2 Assay (Hologic Gen-Probe, San Diego, California) by the Provincial Laboratory for Public Health. Presently, the Gen-Probe Aptima COMBO 2 Assay test is not approved for use from extragenital sites, but has undergone in-laboratory validation and is used in Alberta for C. trachomatis screening from extragenital sites.
Data Collection
An extract of clinic testing data was obtained from the Provincial Laboratory for Public Health between 20 July and 31 December 2012. All positive chlamydia results were matched to chlamydia cases in the provincial STI database to obtain demographics, clinical history, and reasons for their visit. The number of gonorrhea cases detected by each clinic was too small for disease-specific analysis. However, 67% (37/55) of the identified gonorrhea cases were coinfected with chlamydia and are included in the chlamydia analysis. A chart review was conducted to ascertain variables related to drug use and sexual behavior.
Statistical Methods
All statistical analyses were completed on each clinic independently due to significant differences in patient populations and screening criteria. To identify factors associated with rectal C. trachomatis, analyses were performed by comparing rectalpositive chlamydia cases to non-rectal-positive chlamydia cases, as well as comparing rectal-only cases to all other cases (ie, with genitourinary ± rectal site). Univariate analyses were performed using χ 2 or Fisher exact test for categorical variables and MannWhitney tests for continuous variables, excluding missing data. To identify independent factors associated with rectal infection, multivariable log-binomial regression was performed. All variables significant at P ≤ .10 at the univariate level and any potential confounding variables such as AI were included. Variables that were not statistically significant (P < .05) or that did not improve the model were not included in the final model. Analyses were completed using IBM SPSS Statistics 19 (IBM, Armonk, New York) and Stata version 11 (StataCorp, College Station, Texas). Ethics approval was obtained from the University of Alberta's Health Research Ethics Board.
RESULTS
From 20
July through 31 December 2012, 1570 rectal chlamydia specimens were collected at the Calgary clinic and 1485 specimens were collected at the Edmonton clinic (Table 1) . Nearly all rectal screening was accompanied by genitourinary screening (98.3% in Calgary and 94.5% in Edmonton). The median age at time of testing was 28 years (interquartile range [IQR], 24-33 years) in Calgary and 25 years (IQR, 21-32 years) in Edmonton.
The prevalence of chlamydia regardless of the site of infection was 13.0% (n = 204) in Calgary and 17.2% (n = 256) in Edmonton. The prevalence of rectal chlamydia was 11.7% (n = 183) in Calgary and 13.5% (n = 201) in Edmonton. A total of 432 chlamydia cases were identified between the 2 clinics and of these, 356 (82.4%) were rectal positive (Table 1) . At the Calgary clinic, 89.0% (n = 170) were rectal positive, with 42.4% (n = 81) of all chlamydia cases being positive at both the genitourinary and rectal sites. Nearly one-half (46.6%; n = 89) of chlamydia cases were positive solely at the rectal site. At the Edmonton clinic, three-quarters of chlamydia cases (77.1%; n = 186) were rectal positive, with 59.3% (n = 143) of cases positive at both the genitourinary and rectal sites. Only 17.8% (n = 43) of cases were positive solely at the rectal site. The Calgary clinic had a higher proportion of cases positive from the rectum (P = .001) and positive from the rectum only (P < .001) than the Edmonton clinic.
Population differences between the 2 clinics were evident. Cases identified from the Edmonton clinic were younger (median age, 22 years vs 25 years, P < .001) and more likely to be Aboriginal (33.6% vs 7.4%, P < .001), a contact to an STI (33.2% vs 24.2%, P = .04), symptomatic (64.3% vs 46.3%, P < .001), and coinfected with N. gonorrhoeae (13.3% vs 2.6%, P < .001) than those from the Calgary clinic. There were no differences in the proportion of participants reporting AI between the 2 clinics (17.8% in Calgary vs 15.3% in Edmonton, P = .53).
Clinic-specific analyses did not identify any significant differences in demographic factors, sexual behavior, sexual partnering, or clinical features between rectal cases and nonrectal cases reported by the Calgary clinic ( Table 2 ). The only significant difference in cases reported by the Edmonton clinic was a younger median age among rectal cases (22 years vs 25 years, P = .001). There was a trend toward higher rates of N. gonorrhoeae coinfection in rectal cases (15.6%) as compared with nonrectal cases (5.5%); this difference was not statistically significant (P = .07). AI in the last 2 months was reported by <20% of cases with a recorded history (17.8% in Calgary and 15.3% in Edmonton) and there was no association between those reporting AI and having rectal chlamydia (Calgary: 26.3% genitourinary positive vs 16.8% rectal positive, P = .30; Edmonton: 18.6% genitourinary positive vs 14.4% rectal positive, P = .50). Rectal symptoms were reported by only 4 (0.9%) cases from the Calgary clinic; all were rectal positive. Reported symptoms included rectal itching (n = 3) and a papule (n = 1). Because these symptoms do not meet Canadian criteria for the diagnosis of lymphogranuloma venereum (LGV) (Available at: http://www.phac-aspc.gc.ca/publicat/lgv/lgv-rdt1-eng.php), specimens were not submitted for LGV sequencing. Of the 404 cases (93.3%) that were tested for human immunodeficiency virus (HIV) near the time of rectal screening, none was found to be HIV positive. Only 2 cases from each clinic reported sex work.
Through the introduction of rectal screening, the Calgary clinic identified an additional 89 rectal-only cases, increasing case detection by 87.3% from 102 genitourinary cases to 191 total cases. In Edmonton, an additional 43 rectal-only cases were identified, increasing case detection by 21.7%, from 198 genitourinary cases to 241 total cases. Being a contact to an STI was less likely to be associated with having rectal-only chlamydia at both clinics (Calgary: 10.1% vs 36.6%, P < .001; Edmonton: 9.3% vs 38.4%, P < .001; 
DISCUSSION
This is the first Canadian study to examine rectal chlamydia prevalence among female STI clinic attendees. After implementing universal rectal screening on women, our study found that the prevalence of rectal chlamydia ranged from 11.7% to 13.5%, both higher than the 4.7% and 4.8% previously reported among universally screened women but lower than females screened based on reporting AI (14.6%) [9] [10] [11] .
The addition of rectal screening increased case finding. An additional 133 rectal-only cases were identified at both clinics, increasing case detection by 21.7% in Edmonton to 88.2% in Calgary. The increase in case-finding rate in Edmonton falls between reported rates by other universally screened women (14.8%) and women reporting AI (34%) [9, 10] . Calgary's case-finding rate nearly doubled the number of cases. The difference in case finding between the 2 clinics may be related to differences in patient populations and/or to differences in the triage process at the 2 clinics. In Edmonton, individuals without any STI symptoms were triaged to "express testing" and did not undergo rectal screening. Although studies have suggested that "express testing" may increase clinic capacity, one study has suggested that some STI diagnoses may be missed [13] [14] [15] [16] [17] [18] . Van Liere reported that more than one-half of C. trachomatis and N. gonorrhoeae anorectal cases would have been missed if using symptom-and sexual history-based screening vs universal screening [12] . Only 2 of our 89 rectal-only cases in Calgary reported rectal specific symptoms (rectal itching and irritation). Using a symptom-based screening approach, all of the rectalonly cases in Edmonton and nearly all (97.8%) of the cases in Calgary would have been missed. Similarly, exposure-based screening would have had limited impact on case finding, as less than one-quarter rectal-only cases (Calgary, 15.9% and Edmonton, 22.6%) reported AI. There are several possible explanations for the presence of anorectal chlamydia in those without a history of self-reported AI. AI may be underreported, or alternative transmission routes may not be captured by routine history taking [10] . This study did not assess sexual transmission routes other than reported AI. Future studies should examine the association between rectal chlamydia infections and these other potential transmission mechanisms. Underreporting of AI is a possibility; however, our findings that 17% of participants reported AI with partners in the last 2 months are consistent with the estimates of 10%-22% of clients attending STI clinics [10, [19] [20] [21] [22] . We found that rectal cases were more likely to occur among younger participants; there was no association between cases reporting AI and age [10, 22] . In addition, history of AI in the previous 2 months was recorded, which may limit previous history of AI outside this time period and not correctly capture the association between disease and activity. Other studies have suggested that AI among women is a commonly practiced behavior. In a population-based survey in the United States, ever having AI was reported by up to 46% of women surveyed, with 23% of women reporting AI in the previous year, and 8% reporting AI in the previous month [23] . In studies of women at high risk for STIs where condom use was assessed, most of the women reported never using condoms for AI, suggesting increased likelihood of exposure to STIs, including HIV [19, 21] . Another possible explanation for the presence of anorectal C. trachomatis in women with no history of AI is autoinoculation by infected vaginal secretions [24] . The evidence for this is scarce and our study has mixed support for this theory, with the highest concordance of sites in Edmonton (59.3%), dropping to 42.2% in Calgary. We cannot rule out the possibility, however, that the negative tests from genitourinary specimens represent spontaneously cleared infection, as a previous study by Geisler et al reported spontaneous resolution of chlamydia in 18% of infected women prior to treatment [25] .
A third possible explanation may be differences in spontaneous clearance rates between genital and extragenital chlamydia. A study of genital infection resolution rates found that resolution occurred in 11%-44% within a few weeks and that approximately one-half of cases had resolved 1 year after testing [26] . A small retrospective study of rectal C. trachomatis cases found that 18% (2/11) cases had resolved within weeks of initial testing [27] . Further study on clearance rates in extragenital cases is warranted.
A fourth possible explanation is that some of the positive rectal tests using NAAT were false positives; this seems less likely in our study, as a preliminary evaluation of a subset of the positive rectal specimens from this study showed that 76 of 81 rectal specimens testing positive with the Gen-Probe Aptima were confirmed with a second NAAT and/or omp1 sequencing (S. Drews, manuscript in preparation). The most significant factor identified by both clinics was that participants who presented contacts to an STI were less likely to have rectal-only chlamydia and therefore benefit less from the additional screening. Only 1 variable provided a significant difference between cases that were contacts to an STI and other cases among demographic and sexual history variables. Cases from the Edmonton clinic that were a contact to an STI were more likely to be asymptomatic than other cases (46.3% vs 30.4%, P = .02). Perhaps being a contact to an STI causes participants to seek assessment and treatment earlier in the infection before the rectum can become infected if autoinoculation is the cause of the rectal infection. The detection of rectal chlamydia cases has clinical relevance. Recent studies have indicated that azithromycin may not be the most suitable drug for rectal chlamydia [28] [29] [30] . If rectal chlamydia is a hidden reservoir influencing transmission rates, then ensuring the successful treatment of cases is pertinent. The detection of rectal-only cases increases the accuracy of incidence and prevalence data in the population. Routinely screening high-risk women for rectal chlamydia would significantly increase the costs associated with chlamydia screening programs. Chesson et al reported that selective screening for rectal chlamydia and gonorrhea is cost effective in reducing HIV infection in men who have sex with men at a cost per quality-adjusted life-year of US$16 300 [31] . Further studies to examine the cost effectiveness of routine rectal chlamydia screening in high-risk females as well as the long-term effects on health and transmission are warranted.
The Calgary clinic found that additional cases were less likely to be found among those who reported ever having used drugs; however, there was no significant difference in those currently using drugs and having rectal chlamydia. Those who reported ever using drugs had a lower median age than those who did not report drug use (25 years vs 27 years, P = .02). Unfortunately, due to the retrospective nature of the study, specific details on current vs historical drug use and its impact on sexual risk behavior and networks are not available.
A limitation of our study is that we did not assess the type and distribution of C. trachomatis serovars and were thus unable to determine if the infections at different anatomic sites were the same organism or if certain serovars predominated at certain anatomic sites. Several studies have reported a difference in distribution of serovar by anatomic site [32] [33] [34] [35] .
Our findings may not be generalizable to all female STI clinic attendees or the general female population. At the Edmonton clinic, screening criteria used for express testing may have increased the proportion of cases who were symptomatic, had a history of AI, and were contacts to an STI. However, when analyzed by clinic, the presence of symptoms was not found to have a significant association in the bivariate model.
CONCLUSIONS
Our findings add to the growing body of evidence supporting universal rectal screening in high-risk women such as those attending STI clinics. Although the overall personal and public health benefits of the detection of rectal C. trachomatis remain to be elucidated, early detection and treatment are likely to be critical strategies in chlamydia control to prevent complications and reduce transmission [35] . Our study shows that most rectal infections are asymptomatic and confirm previous findings that using a history of AI to screen for rectal chlamydia is not a reliable triaging tool for anatomical site-specific testing [36] . Future studies should examine the cost-effectiveness of rectal chlamydia screening in high-risk women and examine the long-term implications of untreated rectal chlamydia on health and transmission.
Notes
